An Open-label Safety and Efficacy Study of VY-AADC01 Administered by MRI-Guided Convective Infusion Into the Putamen of Subjects With Parkinson's Disease With Fluctuating Responses to Levodopa

Trial Profile

An Open-label Safety and Efficacy Study of VY-AADC01 Administered by MRI-Guided Convective Infusion Into the Putamen of Subjects With Parkinson's Disease With Fluctuating Responses to Levodopa

Active, no longer recruiting
Phase of Trial: Phase I

Latest Information Update: 03 Jul 2017

At a glance

  • Drugs AAV-hAADC (Primary)
  • Indications Parkinson's disease
  • Focus Adverse reactions; Proof of concept
  • Sponsors Voyager Therapeutics
  • Most Recent Events

    • 10 May 2017 According to a Voyager Therapeutics media release, data from this and another study ( CTP700279672) will help inform the design of a planned phase 2 trial (CTP700278957).
    • 25 Apr 2017 According to a Voyager Therapeutics media release, Interim results from cohorts 1 and 2 were presented at the American Association of Neurological Surgeons (AANS) Meeting.
    • 25 Apr 2017 According to a Voyager Therapeutics media release, Interim results from cohorts 1 and 2 were presented at the American Academy of Neurology (AAN) Meeting.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top